Sanara MedTech(US:SMTI) Globenewswire·2026-01-23 12:30Core Viewpoint - Sanara MedTech Inc. reported preliminary financial results for Q4 and full year 2025, indicating strong growth and provided financial guidance for 2026, projecting continued revenue growth driven by surgical products [1][4]. Financial Results - Preliminary net revenue for Q4 2025 is expected to be between $27.2 million and $27.7 million, reflecting a year-over-year increase of approximately 3% to 5% compared to $26.3 million in Q4 2024 [5]. - For the full year 2025, net revenue is projected to be in the range of $102.7 million to $103.2 million, marking a growth of approximately 19% compared to $86.7 million in 2024 [5]. - Excluding BIASURGE sales from Q4 2024, the adjusted net revenue for Q4 2025 is expected to increase by approximately 11% to 13% year-over-year [5][13]. Financial Guidance - The company anticipates full year 2026 net revenue to range from $116 million to $121 million, representing growth of approximately 13% to 17% compared to the midpoint of the expected net revenue for 2025 [4][6]. - The growth in 2026 is expected to be primarily driven by sales of soft tissue products [6]. Operational Highlights - The company secured a new contract with Vizient, enhancing access to BIASURGE products at contracted pricing, effective January 1, 2026 [4][6]. - Sanara plans to introduce the OsStic Synthetic Injectable Structural Bio-Adhesive to the U.S. market in Q1 2027, pending FDA clearance [5][6]. Cash and Debt Position - As of December 31, 2025, the company reported cash of approximately $16.6 million and long-term debt of $46.0 million, compared to cash of $15.9 million and long-term debt of $30.7 million as of December 31, 2024 [5].